Daiichi Sankyo Co Ltd
TSE:4568
Daiichi Sankyo Co Ltd
EPS (Diluted)
Daiichi Sankyo Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
EPS (Diluted)
¥155
|
CAGR 3-Years
65%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-10%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
EPS (Diluted)
¥131
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
7%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
EPS (Diluted)
¥633
|
CAGR 3-Years
40%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
EPS (Diluted)
¥198
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
8%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
EPS (Diluted)
¥249
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
24%
|
|
|
Astellas Pharma Inc
TSE:4503
|
EPS (Diluted)
¥28
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Daiichi Sankyo Co Ltd
Glance View
Daiichi Sankyo Co., Ltd., a cornerstone of Japan's pharmaceutical industry, embarked on its journey in 2005 from the merger of two storied companies, Daiichi Pharmaceutical and Sankyo Co., both with roots stretching back to the early 20th century. They combined their rich histories and expertise to form a global powerhouse in healthcare. Daiichi Sankyo has since developed a compelling narrative in creating innovative pharmaceuticals, with a particular focus on oncology, managing cardiovascular risks, and tackling inflammatory diseases. This dedication is reflected in its flagship product, Enhertu (trastuzumab deruxtecan), a cutting-edge therapy in the field of oncology that has gained considerable global traction and approval for treating HER2-positive cancers. Constantly investing in research and development, the company aims to enhance its portfolio through innovative drugs that fulfill unmet medical needs, thereby driving sustainable growth. The financial engine propelling Daiichi Sankyo forward is fueled by its robust product pipeline and strategic partnerships, such as its collaboration with AstraZeneca. These alliances not only bolster its research capabilities but also extend its market reach, especially in regions where regulatory landscapes can be intricate. While its revenue streams are primarily generated from pharmaceuticals, the company also invests in over-the-counter medications and vaccines, contributing to a diversified revenue base. Daiichi Sankyo’s strategy of maintaining a balanced portfolio, combined with its strategic commitment to pioneering treatments in oncology, aligns with its broader vision of being a leader in the global pharmaceutical arena, translating their scientific discoveries into tangible health solutions worldwide.
See Also
What is Daiichi Sankyo Co Ltd's EPS (Diluted)?
EPS (Diluted)
156
JPY
Based on the financial report for Mar 31, 2025, Daiichi Sankyo Co Ltd's EPS (Diluted) amounts to 156 JPY.
What is Daiichi Sankyo Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-10%
Over the last year, the EPS (Diluted) growth was 49%. The average annual EPS (Diluted) growth rates for Daiichi Sankyo Co Ltd have been 65% over the past three years , 19% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet